KD Logo

KAPA’s latest rating updates from top analysts.

Kairos Pharma Ltd’s filing revealed that its VP of Research and Development Murali Ramachandran acquired Company’s shares for reported $318.0 on Nov 25 ’24. In the deal valued at $1.59 per share,200 shares were bought. As a result of this transaction, Murali Ramachandran now holds 133,057 shares worth roughly $0.2 million.

Then, Samuelson Doug bought 2,500 shares, generating $3,750 in total proceeds. Upon buying the shares at $1.50, the Chief Financial Officer now owns 60,796 shares.

Before that, Yu John S bought 4,000 shares. Kairos Pharma Ltd shares valued at $5,760 were divested by the CEO and Chairman at a price of $1.44 per share. As a result of the transaction, Yu John S now holds 5,341,837 shares, worth roughly $8.12 million.

Price Performance Review of KAPA

On Monday, Kairos Pharma Ltd [AMEX:KAPA] saw its stock jump 6.29% to $1.52. Over the last five days, the stock has lost -0.65%.

Levels Of Support And Resistance For KAPA Stock

The 24-hour chart illustrates a support level at 1.4067, which if violated will result in even more drops to 1.2933. On the upside, there is a resistance level at 1.5767. A further resistance level may holdings at 1.6333. The Relative Strength Index (RSI) on the 14-day chart is 49.39, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0626, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.87%. Stochastics %K at 25.47% indicates the stock is a holding.

How much short interest is there in Kairos Pharma Ltd?

A steep rise in short interest was recorded in Kairos Pharma Ltd stocks on 2024-10-31, dropping by 9818.0 shares to a total of 9605.0 shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 19423.0 shares. There was a decline of -102.22%, which implies that there is a negative sentiment for the stock.

Most Popular